Cas:14174-08-4 benzo-12-crown-4 manufacturer & supplier

Chemical Name:benzo-12-crown-4

CAS.NO:14174-08-4

Synonyms:BENZO-12-CROWN-4;2,3-Benzo-1,4,7,10-tetraoxadodec-2-ene;2,5,8,11-tetraoxabicyclo[10.4.0]hexadeca-1(16),12,14-triene;1,4,7,10-Benzotetraoxacyclododecin, 2,3,5,6,8,9-hexahydro-;2,3,5,6,8,9-Hexahydro-1,4,7,10-benzotetraoxacyclododecine;MFCD00059934

Molecular Formula:C₁₂H₁₆O₄

Molecular Weight:224.253

HS Code:2932999099

Physical and Chemical Properties:

Melting point:42-45 °C(lit.)

Boiling point:341.8±37.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.479

PSA:36.92000

Exact Mass:224.104858

LogP:0.78

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like BENZO-12-CROWN-4 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00059934 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00059934 Use and application,BENZO-12-CROWN-4 technical grade,usp/ep/jp grade.

Related News: The business, home to popular brands such as arthritis gel Voltaren and vitamins line Centrum, generated over £10 billion in sales during 2020. 2,4-Diphenyloxazole manufacturers CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication. ethyl 1-oxo-2H-isoquinoline-4-carboxylate suppliers Exploring biocatalysis options at the start of a project is a pragmatic operational strategy to achieve the right product, at the right quality, with exceptional efficiency. dihydroterpinyl acetate vendor & factory The business, home to popular brands such as arthritis gel Voltaren and vitamins line Centrum, generated over £10 billion in sales during 2020.,CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication.